QVance AB Announces Nordic Partnership with bioMérieux
QVance AB, Huddinge, Sweden has today announced it has entered into a partnership with bioMérieux Sweden AB, aimed at enhancing the quality analytics offerings in microbiology and mycoplasma testing for cell and gene therapy product development and release
bioMérieux, a world leader in the field of in vitro diagnostics, pioneer, develop and produce high quality diagnostic solutions to improve public health worldwide. This collaboration will leverage the strengths of both companies to offer innovative solutions and support the advanced therapy community in the Nordics. QVance, in addition to offering bioMérieux’s testing solutions, will offer an opportunity for customers to visit QVance’s site in Stockholm and see firsthand bioMeriéux’s technology. Together, the companies will support the development of rapid and compliant quality control testing methods for advanced therapies in the Nordics.
"The partnership with bioMérieux represents a significant step forward in the establishment of QVance. Collaboration with a global leader such as bioMerieux in our startup phase highlights the clear need for QC analytic provision in the Nordics for the advanced therapy sector, and we are happy to be at the forefront of this development," said Lindsay Davies, CSO of QVance’s parent company NextCell Pharma AB and co-founder of QVance.
The partnership is expected to expand QVance’s service offerings as well as provide education and support with joint webinars and communications to advanced therapy companies in the Nordics. Both companies are committed to maintaining their high standards of quality and innovation as they work together to achieve mutual goals.
“Our ambition is to be the partner of choice for smart quality control of cell and gene therapy manufacturers”, says David Bates, Business Development Manager for Cell & Gene Therapies at bioMérieux. “We are excited about this collaboration with QVance to further support this critical area of modern healthcare and contribute to bringing those advanced therapies to the patients faster.”
QVance and bioMerieux will begin implementing joint initiatives immediately, with the launch of QVance at ATMP Sweden in Malmö on November 25th 2024.
For more information, please contact:
Lindsay Davies
QVance AB
Email: info@qvance.se
Website: www.qvance.se
LinkedIn https://www.linkedin.com/company/qvance/
QVance AB is the daughter company of NextCell Pharma AB
For more information regarding NextCell Pharma please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
About QVance AB
QVance is a quality analytics service provider for advanced therapies. The company’s vision is to be a one-stop analytics service supporting customers throughout development and drug product lifecycle.